Reported Earlier, Genmab's Epcoritamab Receives EMA Opinion for Follicular Lymphoma Treatment
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S (NASDAQ:GMAB) announced that the EMA's CHMP has adopted a positive opinion recommending conditional marketing authorization for epcoritamab (TEPKINLY®) for treating relapsed or refractory follicular lymphoma. The final decision by the European Commission is expected later this year.
June 28, 2024 | 7:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab's epcoritamab has received a positive opinion from the EMA's CHMP for conditional marketing authorization to treat relapsed or refractory follicular lymphoma. The final decision by the European Commission is anticipated later this year.
The positive opinion from the EMA's CHMP is a significant regulatory milestone for Genmab's epcoritamab, potentially leading to conditional marketing authorization. This could open up a new market in the EU for the treatment of relapsed or refractory follicular lymphoma, positively impacting Genmab's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100